VAN WIJMEERSCH, Bart

Email Alert RSS Feed

Profile

Full Name
VAN WIJMEERSCH, Bart
Email
bart.vanwijmeersch@uhasselt.be
 
Loading... 5 0 5 0 false
Loading... 6 0 5 0 false

Publications

Refined By:
Author:  VAN WIJMEERSCH, Bart
Date Issued:  2016
Internal UHasselt:  VAN WIJMEERSCH, Bart

Results 1-10 of 10 (Search time: 0.004 seconds).

Issue DateTitleContributor(s)TypeCat.
12016B cells of multiple sclerosis patients induce autoreactive proinflammatory T cell responsesFRAUSSEN, Judith; CLAES, Nele; VAN WIJMEERSCH, Bart; VAN HORSSEN, Jack; STINISSEN, Piet; Hupperts, Raymond; SOMERS, VeerleJournal ContributionA1
22016Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).Coles, A. J.; Boyko, A. N.; Cohen, J. A.; De Seze, J.; Fox, E. J.; Havrdova, E.; Hartung, H. -P.; Inshasi, J. S.; McCombe, P.; Selmaj, K. W.; Vermersch, P.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.; Montalban, X.Journal ContributionM
32016Effects of an individual 12 weeks community located running program on physical capacity, walking, cognitive function, dual tasking and brain volumes and structures in persons with Multiple Sclerosis.FEYS, Peter; MOUMDJIAN, Lousin; Vanhalewyck, F.; WENS, Inez; OP 'T EIJNDE, Bert; VAN WIJMEERSCH, Bart; POPESCU, Veronica; Dufour, A.; Delva, S.; VAN ASCH, PaulJournal ContributionM
42016Durable reduction in MRI disease activity with alemtuzumab in treatment-naive patients with active relapsing-remitting multiple sclerosis: 6-year follow-up of the CARE-MS I studyArnold, D. L.; Barnett, M.; Comi, G.; Giovannoni, G.; Pelletier, D.; Rovira, A.; Schippling, S.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Traboulsee, A.Journal ContributionM
52016Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatmentBermel, R.; Comi, G.; Eralinna, J. -P.; Leist, T. P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Bernasconi, C.; Buffels, R.; Csoboth, C.; Han, J.; Musch, B.; Vermersch, P.Journal ContributionM
62016Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)Oreja-Guevara, C.; Alroughani, R.; Brassat, D.; Boyko, A. N.; McCombe, P.; Steingo, B.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.; Vermersch, P.Journal ContributionM
72016Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis PatientsCLAES, Nele; FRAUSSEN, Judith; VANHEUSDEN, Marjan; HELLINGS, Niels; STINISSEN, Piet; VAN WIJMEERSCH, Bart; Hupperts, Raymond; SOMERS, VeerleJournal ContributionA1
82016Effects of teriflunomide treatment on the CD4(+) T-cell receptor repertoire in patients with relapsing-remitting MSKlotz, Luisa; Lindner, Maren; Gross, Catherina C.; Eschborn, Melanie; Posevitz-Fejfar, Anita; Schulte-Mecklenbeck, Andreas; Meuth, S. G.; VAN WIJMEERSCH, Bart; Hupperts, Raymond; Maeurer, M.; Stangel, M.; Lang, M.; Tackenberg, B.; Lysandropoulos, A.; Decoo, D.; Eveslage, M.; Turner, Timothy J.; Jagerschmidt, A.; Bar-Or, Amit; Wiendl, HeinzJournal ContributionM
92016Brain atrophy by automated MRI reading in long-term natalizumab treated patients: Real world data suggests brain atrophy rates in range of healthy individualsHorakova, Dana; Uher, T.; Vaneckova, M.; Krasensky, J.; Seidl, Z.; van Pesch, V.; Lysandropoulos, A.; VAN WIJMEERSCH, Bart; Ribbens, A.; van Hecke, W.; Dong, Q.; Farkas, M.; Hyde, R.; Koendgen, H.Journal ContributionM
102016Upper Limb Rehabilitation in People With Multiple Sclerosis: A Systematic ReviewLAMERS, Ilse; MARIS, Anneleen; SEVERIJNS, Deborah; Dielkens, Wouter; Geurts, Sander; VAN WIJMEERSCH, Bart; FEYS, PeterJournal ContributionA1